

Appendix G: STROBE Statement

Table 1: STROBE Checklist-Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation	Section
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	n.a.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title, Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	1
Objectives	3	State specific objectives, including any prespecified hypotheses	1
Methods			

Continued on next page.

047 Table 1 – continued from previous page
048

049		Item No	Recommendation	Section
050				
051	Study design	4	Present key elements of	2.1
052			study design early in the	
053			paper	
054				
055				
056	Setting	5	Describe the setting,	2.1
057			locations, and relevant	
058			dates, including periods	
059			of recruitment, expo-	
060			sure, follow-up, and	
061			data collection	
062				
063				
064				
065				
066	Participants	6	(a) Give the eligibil-	2.1-2.3
067			ity criteria, and the	
068			sources and methods	
069			of selection of partic-	
070			ipants. Describe meth-	
071			ods of follow-up	
072				
073				
074				
075				
076			(b) For matched studies,	n.a.
077			give matching criteria	
078			and number of exposed	
079				
080				
081			and unexposed	

Continued on next page.

Table 1 – continued from previous page

	Item No	Recommendation	Section
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	2.1
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	2.1
Bias	9	Describe any efforts to address potential sources of bias	2.2-2.6
Study size	10	Explain how the study size was arrived at	2.1

Continued on next page.

139 Table 1 – continued from previous page
 140

141		Item No	Recommendation	Section
142				
143	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	n.a.
144				
145				
146				
147				
148				
149				
150				
151				
152				
153	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	2.2-2.6
154				
155				
156				
157				
158				
159				
160			(b) Describe any methods used to examine subgroups and interactions	n.a.
161				
162				
163				
164				
165				
166			(c) Explain how missing data were addressed	2.1
167				
168				
169				
170			(d) If applicable, explain how loss to follow-up was addressed	n.a.
171				
172				
173				
174				
175			(e) Describe any sensitivity analyses	n.a.
176				
177				

178 **Results**
 179

180 Continued on next page.
 181

182
 183
 184

Table 1 – continued from previous page

	Item No	Recommendation	Section
Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	Appendix C
		(b) Give reasons for non-participation at each stage	n.a.
		(c) Explain how missing data were addressed	Appendix C
Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	3.1
		(b) Indicate number of participants with missing data for each variable of interest	n.a.

Continued on next page.

231 Table 1 – continued from previous page
232

233		Item No	Recommendation	Section
234				
235			(c) Summarize follow-up	n.a.
236			time (eg, average and	
237			total amount)	
238				
239				
240	Outcome data	15	Report numbers of	3.1
241			outcome events or sum-	
242			mary measures over	
243			time	
244				
245				
246				
247	Main results	16	(a) Give unadjusted	3.4-3.5
248			estimates and, if	
249			applicable, confounder-	
250			adjusted estimates and	
251			their precision (eg, 95%	
252			confidence interval).	
253			Make clear which con-	
254			founders were adjusted	
255			for and why they were	
256			included	
257			(b) Report category	n.a.
258			boundaries when con-	
259			tinuous variables were	
260			categorized	
261				
262				
263				
264				
265				
266				
267				
268				
269				

270 Continued on next page.

271
272
273
274
275
276

Table 1 – continued from previous page

	Item No	Recommendation	Section
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n.a.
Other analyses	17	Report other analyses done — eg analyses of subgroups and interactions, and sensitivity analyses	3.6
Discussion			
Key results	18	Summarize key results with reference to study objectives	4
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	4

Continued on next page.

Table 1 – continued from previous page

	Item No	Recommendation	Section
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	4
Generalisability	21	Discuss the generalisability (external validity) of the study results	5
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Declarations